High Demand for Drug to Prevent Covid in the Vulnerable, Yet Doses Go Unused
Sasha Mallett, Sue Taylor and Kimberly Cooley all have immune deficiencies that make them especially vulnerable to COVID-19, and all…
COVID May Affect Spinal Fluid, Causing ‘Brain Fog,’ Study Says
Ralph Ellis – January 21, 2022 Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource…
Stuart Schlossman
January 2022 – This message is geared towards people with MS – about how to get reimbursement for home tests/get free home tests
Reimbursing Your At-Home COVID-19 Tests January 24, 2022 On January 10, 2022, the Biden Administration issued guidance that required private…
Stuart Schlossman
Evusheld for Pre-exposure Prevention of COVID-19 – This prevention medication is strictly for those who are not expected to have adequate immune responses to the vaccine
Last updated: December 17, 2021 The U.S. Food and Drug Administration (FDA) has authorized Evusheld (tixagevimab co-packaged with cilgavimab) as a…
Stuart Schlossman
COVID-19 Studies Recruiting People with MS
Overview The National MS Society is partnering with organizations and supporting research that seeks to understand the impacts of…
Stuart Schlossman
Delaying b-cell depleters (Ocrevus, kesimpta, rituximab) increases the chance of getting protective antibodies after covid-19 vaccination
January 13, 2022 Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals? Abstract Although there is an…
Stuart Schlossman
COVID-19 Vaccine Response in People with Multiple Sclerosis
Abstract Objective: The purpose of this study was to investigate the effect of disease modifying therapies on immune response to…
Stuart Schlossman
Learning about MS Diagnosis & MS Symptoms, plus COVID updates – presented by Aaron Boster, MD
Watch Dr. Aaron Boster present …
Stuart Schlossman
Study: Anti-CD20 Therapies, Gilenya Lower Efficacy of COVID-19 Vaccines
Certain treatments for multiple sclerosis (MS) — specifically, anti-CD20 antibody therapies and Gilenya (fingolimod) — are likely to reduce the effectiveness of vaccines…
Stuart Schlossman
COVID-19 Vaccine Reactions in People with MS Similar to General Population, Says New Society-Funded Study
November 17, 2021 Surveys of hundreds of people with MS enrolled in the iConquerMS network reveal that reactions to COVID-19…
Stuart Schlossman
